India markets open in 1 hour 52 minutes

63 moons technologies limited (63MOONS.BO)

BSE - BSE Real Time Price. Currency in INR
Add to watchlist
98.75+2.80 (+2.92%)
At close: 3:42PM IST
Full screen
Previous close95.95
Open95.95
Bid98.75 x 0
Ask98.65 x 0
Day's range95.95 - 102.30
52-week range39.75 - 102.30
Volume125,434
Avg. volume28,312
Market cap4.55B
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings date31-Jul-2020
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est261.00
  • GlobeNewswire

    ATEC Extends InVictus MIS Platform With Commercial Release of InVictus MIS Tower

    Elevates MIS posterior fixation optionality         Robust instrumentation designed to treat more complex pathologies less invasivelyCARLSBAD, Calif., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Alphatec Holdings, Inc. (“ATEC” or the “Company”) (Nasdaq: ATEC), a medical device company dedicated to revolutionizing the approach to spine surgery, announced today the commercial release of the InVictus™ MIS Tower, an elegant and intuitive system designed for minimally invasive percutaneous fixation. InVictus MIS Tower is the next evolution of InVictus™, ATEC’s comprehensive spinal fixation platform, engineered to treat a range of pathologies with intraoperative adaptability and surgical predictability through open, MIS, or hybrid approaches.“The novel components designed into the InVictus Platform are the result of ATEC being willing to invest where others won’t – in the procedural requirements that improve surgical outcomes,” said Pat Miles, Chairman and Chief Executive Officer. “The InVictus MIS Tower system is an important addition to our comprehensive posterior solution as it opens the door for surgeons to increasingly partner with ATEC for MIS degenerative and deformity applications. We are committed to continuing to develop differentiated, integrated solutions in order to expand surgeon adoption and loyalty, and to better serve patients.”Developed to enhance the capability of percutaneous fixation systems, InVictus MIS Tower expands upon the foundational elements of the InVictus platform allowing for the treatment of more complex pathologies through a less disruptive manner. InVictus Tower features two low-profile removable towers, engineered to reliably stay secured to cannulated dual-lead polyaxial screws to improve control and to support long construct manipulation.When paired with the SingleStep™ technique, the MIS Tower system extends the dependability and predictability of InVictus MIS fixation and can obviate the need for guide wires, which can lead to surgical complications. It seamlessly integrates with SafeOp™ Neural InformatiX System combined EMG technology to predictably deliver real-time, actionable information during pedicle preparation and screw insertion. InVictus MIS Tower also couples with InVictus MOD and InVictus OPEN to streamline in situ tulip attachment, acting as an efficient guide for reliable rod passage and adapting intraoperatively to the surgical requirements of any procedure.Tyler G. Smith, MD, of the Sierra Spine Institute in Roseville, CA, commented, “The InVictus Tower System has clearly been designed to more reproducibly address complex pathologies in a less disruptive manner. Its low-profile, yet robust instrumentation and adaptability take the guesswork out of minimally invasive surgery.  The Tower System integrates seamlessly with the SingleStep technique and SafeOp Advanced Neuromonitoring to beget a comprehensive posterior approach that I can depend on for successful surgical outcomes."K. Brandon Strenge, MD, an orthopaedic spine surgeon at the Orthopaedic Institute of Western Kentucky, added, “Achieving compression through percutaneous incision in either a short or long construct has long been incredibly challenging. In my hands, the InVictus Tower Compressor is a game changer. Unlike other systems I’ve used, the Tower Compressor seats inside the towers and compresses along the contour of the lordotic rod, easily inducing compression and enabling me to preserve or create lordosis as needed per patient.”Key Features of the InVictus MIS Tower System * Integrates with SafeOp Neural InformatiX System to predictability provide surgeons with real-time, actionable information to detect and monitor the health of nerves at risk during posterior fixation * Adapts intraoperatively to surgical requirements with robust instruments and customizable implants designed to accept multiple rod diameters and materials, which enables the treatment of more advanced pathologies * Leverages helical flange tulip technology to create a dependable construct by reducing cross-thread potential and helping eliminate tulip splay * Features multiple Towers, to reduce tissue disruption without compromising instrument strength * Introduces unique MIS Lordotic Visual Indicator Rods designed to confidently indicate sufficient rod overhang * Integrates with SingleStep technique, which is designed to improve efficiency, reduce radiation, and obviate the need for guide wires, which may lead to complicationsAbout Alphatec Holdings, Inc.Alphatec Holdings, Inc. (ATEC), through its wholly-owned subsidiaries, Alphatec Spine, Inc. and SafeOp Surgical, Inc., is a medical device company dedicated to revolutionizing the approach to spine surgery through clinical distinction. ATEC’s Organic Innovation Machine is focused on developing new approaches that integrate seamlessly with the SafeOp Neural InformatiX System to safely and reproducibly treat spine’s various pathologies and achieve the goals of spine surgery. Alphatec’s vision is to become the Standard Bearer in Spine. For more information, visit us at www.atecspine.com.Forward Looking Statements   This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainty. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The Company cautions investors that there can be no assurance that actual results will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors. Forward-looking statements include references to the Company’s planned commercial launches, product introductions and product integration, surgeon and market acceptance of Company products, solutions and platforms, and the Company’s ability to deliver key product features. The important factors that could cause actual operating results to differ significantly from those expressed or implied by such forward-looking statements include, but are not limited to: the uncertainty of success in developing new products or products currently in the Company’s pipeline; failure to achieve acceptance of the Company’s products by the surgeon community; failure to obtain FDA or other regulatory clearance or approval for new products, or unexpected or prolonged delays in the process; continuation of favorable third party reimbursement for procedures performed using the Company’s products; the Company’s ability to compete with other products and with emerging new technologies; product liability exposure; patent infringement claims; and claims related to the Company’s intellectual property.  The words “believe,” “will,” “should,” “expect,” “intend,” “estimate,” “look forward” and “anticipate,” variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. A further list and description of these and other factors, risks and uncertainties can be found in the Company's most recent annual report, and any subsequent quarterly and current reports, filed with the Securities and Exchange Commission. ATEC disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.Company Contact:Jeff Black Chief Financial Officer Alphatec Holdings, Inc.  ir@atecspine.comInvestor/Media Contact:Tina Jacobsen Investor Relations  (760) 494-6790 ir@atecspine.com

  • GlobeNewswire

    ATEC Announces Closing of Public Stock Offering and Full Exercise of Underwriters’ Option to Purchase Additional Stock

    CARLSBAD, Calif., Oct. 16, 2020 (GLOBE NEWSWIRE) -- Alphatec Holdings, Inc. (“ATEC”) (NASDAQ: ATEC), a provider of innovative spine surgery solutions dedicated to revolutionizing the approach to spine surgery, today announced the closing of its previously announced underwritten public offering of 13,142,855 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 1,714,285 additional shares of common stock, at a public offering price of $8.75 per share, for total gross proceeds of approximately $115.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by ATEC. Morgan Stanley and Cowen acted as joint book-running managers in the offering. Canaccord Genuity acted as lead manager in the offering, with Lake Street Capital Markets and Northland Capital Markets acting as co-managers.The shares of common stock were offered pursuant to a shelf registration statement on Form S-3 (File No. 333-241677) previously filed with and declared effective by the Securities and Exchange Commission. The offering was made by means of a prospectus supplement and the accompanying prospectus. A preliminary prospectus supplement and accompanying prospectus relating to the offering were filed previously with the SEC and are available on the SEC’s website at www.sec.gov. The final prospectus supplement and accompanying base prospectus will be filed with the SEC and available on the SEC’s website thereafter, and, when available, may also be obtained from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, or by e-mail at prospectus@morganstanley.com or Cowen and Company, LLC, at c/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com.This press release shall not constitute an offer to sell nor the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About ATEC Alphatec Holdings, Inc. (ATEC), through its wholly-owned subsidiaries, Alphatec Spine, Inc. and SafeOp Surgical, Inc., is a medical device company dedicated to revolutionizing the approach to spine surgery through clinical distinction. ATEC’s Organic Innovation Machine is focused on developing new approaches that integrate seamlessly with the SafeOp Neural InformatiX System to safely and reproducibly treat spine’s various pathologies and achieve the goals of spine surgery. Alphatec’s vision is to become the Standard Bearer in Spine. For more information, visit us at www.atecspine.com.Company Contact: Jeff Black Chief Financial Officer investorrelations@atecspine.comInvestor/Media Contact: Tina Jacobsen Investor Relations (760) 494-6790 investorrelations@atecspine.com

  • GlobeNewswire

    ATEC Announces Pricing of Public Offering of Common Stock

    CARLSBAD, Calif., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Alphatec Holdings, Inc. (“ATEC”) (NASDAQ: ATEC), a provider of innovative spine surgery solutions dedicated to revolutionizing the approach to spine surgery, today announced the pricing of an underwritten public offering of 11,428,570 shares of its common stock at a public offering price of $8.75 per share.  The gross proceeds to ATEC from the offering, before underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $100 million. In connection with the offering, ATEC has granted the underwriters a 30-day option to purchase up to an additional 1,714,285 shares of common stock at the public offering price, less underwriting discounts and commissions.  All of the shares in the offering are to be sold by ATEC. The offering is expected to close on October 16, 2020, subject to the satisfaction of customary closing conditions.Morgan Stanley and Cowen are acting as joint book-running managers in the offering. Canaccord Genuity is acting as lead manager in the offering, with Lake Street Capital Markets and Northland Capital Markets acting as co-managers.The shares of common stock are being offered pursuant to a shelf registration statement on Form S-3 (File No. 333-241677) previously filed with and declared effective by the Securities and Exchange Commission. The offering is being made only by means of a prospectus supplement and the accompanying prospectus. A preliminary prospectus supplement and accompanying prospectus relating to the offering have been previously filed with the SEC and are available on the SEC’s website at www.sec.gov. The final prospectus supplement and accompanying base prospectus will be filed with the SEC and available on the SEC’s website thereafter, and, when available, may also be obtained from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, or by e-mail at prospectus@morganstanley.com or Cowen and Company, LLC, at c/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com.This press release shall not constitute an offer to sell nor the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About ATEC Alphatec Holdings, Inc. (ATEC), through its wholly-owned subsidiaries, Alphatec Spine, Inc. and SafeOp Surgical, Inc., is a medical device company dedicated to revolutionizing the approach to spine surgery through clinical distinction.  ATEC’s Organic Innovation Machine is focused on developing new approaches that integrate seamlessly with the SafeOp Neural InformatiX System to safely and reproducibly treat spine’s various pathologies and achieve the goals of spine surgery.  Alphatec’s vision is to become the Standard Bearer in Spine. Forward-Looking StatementsThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainty. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. ATEC cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors. The words “believe,” “will,” “should,” “expect,” “intend,” “estimate,” “look forward” and “anticipate,” variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. A further list and description of these and other factors, risks and uncertainties can be found in ATEC’s most recent annual report, any subsequent quarterly and current reports, and certain other filings, filed with the Securities and Exchange Commission. ATEC disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.Company Contact: Jeff Black Chief Financial Officer investorrelations@atecspine.comInvestor/Media Contact: Tina Jacobsen Investor Relations (760) 494-6790 investorrelations@atecspine.com